{"url":"https://lda.senate.gov/api/v1/filings/a24c2b40-bbbd-4bcb-803f-0745780eaa2e/","filing_uuid":"a24c2b40-bbbd-4bcb-803f-0745780eaa2e","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/a24c2b40-bbbd-4bcb-803f-0745780eaa2e/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Ryan Kane","dt_posted":"2026-07-18T14:55:02-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"9650 Nansemond Bay St","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Norfolk","registrant_state":"VA","registrant_zip":"23518","registrant":{"id":401107835,"url":"https://lda.senate.gov/api/v1/registrants/401107835/","house_registrant_id":56186,"name":"RK STRATEGIES, INC.","description":null,"address_1":"9650 Nansemond Bay St","address_2":null,"address_3":null,"address_4":null,"city":"Norfolk","state":"VA","state_display":"Virginia","zip":"23518","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"RYAN KANE","contact_telephone":"+1 336-383-6805","dt_updated":"2026-07-19T14:41:48.716054-04:00"},"client":{"id":67871,"url":"https://lda.senate.gov/api/v1/clients/67871/","client_id":67871,"name":"CLEARMIND MEDICINE, INC","general_description":"Developer of Psychedelics Medicines","client_government_entity":null,"client_self_select":false,"state":"BC","state_display":"British Columbia","country":"CA","country_display":"Canada","ppb_state":"BC","ppb_state_display":"British Columbia","ppb_country":"CA","ppb_country_display":"Canada","effective_date":"2025-06-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R. 7091, Expanding Veterans Access to Emerging Treatments Act H.R.2623, Innovative Therapies Centers of Excellence Act of 2025 H.R. 8800, National Defense Authorization Act for Fiscal Year 2027 H.R. 9237 - Take Care of Americas Veterans Act H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Addiction Related Issues","foreign_entity_issues":"Clearmind Medicine Inc., is principally located in Canada and Israel","lobbyists":[{"lobbyist":{"id":143970,"prefix":null,"prefix_display":null,"first_name":"RYAN","nickname":null,"middle_name":null,"last_name":"KANE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"H.R. 7091, Expanding Veterans Access to Emerging Treatments Act H.R.2623, Innovative Therapies Centers of Excellence Act of 2025 H.R. 8800, National Defense Authorization Act for Fiscal Year 2027 H.R. 9237 - Take Care of Americas Veterans Act H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Addiction Related Issues","foreign_entity_issues":"Clearmind Medicine, Inc principally operates as a Canadian and Israeli company","lobbyists":[{"lobbyist":{"id":143970,"prefix":null,"prefix_display":null,"first_name":"RYAN","nickname":null,"middle_name":null,"last_name":"KANE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"H.R. 7091, Expanding Veterans Access to Emerging Treatments Act H.R.2623, Innovative Therapies Centers of Excellence Act of 2025 H.R. 8800, National Defense Authorization Act for Fiscal Year 2027 H.R. 9237 - Take Care of Americas Veterans Act H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Addiction Related Issues Other Psychedelic Medicine Issues","foreign_entity_issues":"Clearmind Medicine, Inc. principally operates as a Canadian and Israeli company","lobbyists":[{"lobbyist":{"id":143970,"prefix":null,"prefix_display":null,"first_name":"RYAN","nickname":null,"middle_name":null,"last_name":"KANE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"H.R. 7091, Expanding Veterans Access to Emerging Treatments Act H.R.2623, Innovative Therapies Centers of Excellence Act of 2025 H.R. 8800, National Defense Authorization Act for Fiscal Year 2027 H.R. 9237 - Take Care of Americas Veterans Act H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Addiction Related Issues Psychedelic Medicine Issues","foreign_entity_issues":"Clearmind Medicine, Inc. principally operates as a Canadian and Israeli company","lobbyists":[{"lobbyist":{"id":143970,"prefix":null,"prefix_display":null,"first_name":"RYAN","nickname":null,"middle_name":null,"last_name":"KANE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}